Clinical Trial Update: Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain [Phase 3]

View source ↗

Summary

This clinical trial update reports the termination of a Phase 3 study evaluating the fentanyl transdermal matrix patch ZR-02-01 for chronic non-malignant pain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• Fentanyl Transdermal Matrix Patch ZR-02-01 (fentanyl)

Snippet

Sponsor: ZARS Pharma Inc. | Conditions: Pain | Phase 3 | Status: TERMINATED